Youn H Kim

Back to Profile

Publication Details

  • Final results from a multicenter, international, pivotal study of romidepsin in refractory cutaneous T-cell lymphoma.

    Whittaker SJ, Demierre MF, Kim EJ, Rook AH, Lerner A, Duvic M, Scarisbrick J, Reddy S, Robak T, Becker JC, Samtsov A, McCulloch W, Kim YH. J Clin Oncol. 2010; 28 (29): 4485-91

    The primary objective of this study was to confirm the efficacy of romidepsin in patients with treatment refractory cutaneous T-cell lymphoma (CTCL).

    PubMedID: 20697094

Stanford Medicine Resources:

Footer Links: